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Abstract Tryptophan synthase (TrpS) has emerged as a paragon of 
noncanonical amino acid (ncAA) synthesis and is an ideal biocatalyst 
for synthetic and biological applications. TrpS catalyzes an 
irreversible, C–C bond forming reaction between indole and serine 
(Ser) to make L-tryptophan (Trp); native TrpS complexes possess 
fairly broad specificity for indole analogs, but are difficult to engineer 
to extend substrate scope or to confer other useful properties due to 
allosteric constraints and their heterodimeric structure. Directed 
evolution freed the catalytically relevant TrpS β-subunit (TrpB) from 
allosteric regulation by its TrpA partner and has enabled dramatic 
expansion of the enzyme’s substrate scope. This review examines the 
long and storied career of TrpS from the perspective of its application 
in ncAA synthesis and biocatalytic cascades. 
1. Introduction 
Noncanonical amino acids (ncAAs) enable researchers to 
interact with and modify life at the molecular level and are a vital 
tool for many modern biological studies. Defined as amino acids 
that are not genetically encoded, ncAAs bear chemical motifs not 
found in the 20 canonical amino acids and can alter the 
characteristics of molecules that incorporate them. Though often 
referred to as unnatural amino acids, many ncAAs do occur 
naturally as post-translationally modified peptide residues or as 
intermediates in biosynthesis of secondary metabolites.[1] Nature 
thus demonstrates that ncAAs can serve as handles to 
manipulate biochemical properties. Furthermore, substituting 
canonical amino acids with ncAAs imbues molecules with 
different functionalities while minimally perturbing structure.[2] As 
such, ncAAs are seeing growing applications in research, where 
they are useful as biophysical probes,[2,3] are introduced into 
polypeptides to create improved or entirely new functions,[4,5] and 
are incorporated into bioactive small molecules and peptide 
therapeutics.[6–8]  
A barrier to realizing the potential of ncAAs is that they are 
challenging to synthesize owing to laborious protection and 
deprotection sequences necessary to prevent epimerization of 
the chiral center or undesired reactivity with the amine and 
carboxylate groups.[9] Simpler, more effective, and more direct 
routes to ncAAs are necessary to better harness their potential 
applications. A promising approach for ncAA synthesis is to use 
enzymes, which can perform transformations with exquisite 
precision in the presence of multiple reactive centers without the 
need for protecting groups. With carefully tuned active sites, 
enzymes can overcome regio- and stereoselectivity challenges by 
directing substrates and reactive intermediates during a catalytic 
cycle. Another major advantage of enzymes is that they can be 
combined in one-pot biocatalytic cascades to access value-added 
products from simple and inexpensive starting materials.[10] 
However, enzymes from biosynthetic pathways to naturally 
occurring ncAAs may not be practical to engineer or scale up if, 
for example, they catalyze reversible reactions, express poorly in 
recombinant hosts, are allosterically regulated, or have limited 
substrate scopes.[11] Nevertheless, directed evolution has 
empowered biocatalysis to be well poised to contribute to ncAA 
synthesis, and examples of new, engineered ncAA synthases and 
enzyme cascades are emerging.[11] 
Tryptophan synthase (TrpS) is a premier example of an 
enzyme that can be used for scalable ncAA synthesis. TrpS 
possesses covetable qualities for an ncAA synthase: it forms a 
C–C bond between readily available starting materials to make L-
tryptophan (Trp) and closely related derivatives in a single 
enzymatic step.[12] TrpS exists as a heterodimeric complex 
comprised of two α- and β-subunits (TrpA and TrpB, respectively) 
that work together to transform indole glycerol phosphate (IGP) 
and L-serine (Ser) into Trp (Scheme 1). The TrpA subunit is 
responsible for the cleavage of IGP into indole and 
glyceraldehyde, and does not directly participate in the C–C bond 
forming step. In fact, TrpA can be bypassed entirely by providing 
indole analogs to the enzyme complex, where they are 
transformed by the TrpB subunit into Trp analogs. Although TrpS 
can be used to synthesize a variety of Trp-based ncAAs, directed 
evolution of the catalytically relevant TrpB subunit to create a 
stand-alone enzyme dramatically simplified engineering efforts 
and allowed for a systematic expansion of accessible ncAA 
products.[13] 
This review provides an overview of how TrpS and its 
laboratory-evolved TrpB progeny have been used to produce 
ncAAs. We also give examples of how this enzyme has been 
incorporated in biocatalytic cascades to access D-amino acids 
and tryptamine products.  
1.1. Properties of tryptophan synthase (TrpS) 
Tryptophan synthase is a pyridoxal 5’-phosphate (PLP)-
dependent enzyme that has captured the interest of 
enzymologists and bioengineers for over half a century. The study 
of TrpS dates back to when the burgeoning field of molecular 
biology had barely taken its first steps. Discovered in the 1940s, 
TrpS has served as a model enzyme for a wide range of 
investigations, from proving gene-protein collinearity[14] to 
studying the evolution and nature of allostery,[15] conceptualizing 
and understanding vectorial catalysis and substrate 
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channeling,[16] and, most relevant to this review, synthesis of 
ncAAs. 
TrpS is found in all domains of life as an αββα heterodimeric 
complex that catalyzes the formation of Trp from IGP and Ser 
(Scheme 1). The α-subunit (TrpA) and β-subunit (TrpB) 
experience mutual allosteric activation, the evolutionary history 
and nature of which are still an active area of research.[17,18] The 
two subunits interact with one another through rigid-body motion 
of the TrpB communication (COMM) domain and a monovalent 
cation (MVC) binding site within TrpB. When IGP binds TrpA, it 
initiates a conformational change activating TrpB to promote 
formation of the (PLP)-bound amino-acrylate derived from Ser. 
The TrpB subunit then reciprocally stimulates TrpA to induce 
retro-aldol cleavage of IGP, releasing indole.[19] Once released, 
indole diffuses along a 25-Å long tunnel to the β-subunit where it 
can immediately participate in a PLP-mediated β-addition reaction, 
releasing water and Trp. 
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Scheme 1. Native transformation catalyzed by TrpS. TrpA (left, pink) performs 
a retro-aldol cleavage on indole glycerol phosphate (IGP) releasing indole and 
glyceraldehyde phosphate. Indole diffuses to the TrpB subunit (right, green) 
which catalyzes a PLP-mediated β-substitution reaction between indole and L-
serine (Ser), releasing water and L-tryptophan (Trp). (PDB:5E0K) 
The TrpB PLP cofactor absorbs in the UV-vis region, and 
each reactive intermediate possesses a characteristic spectral 
trace, allowing observation of the catalytic cycle via UV-vis 
spectroscopy. In the TrpB resting state, PLP is covalently bound 
to the ε-nitrogen of a lysine residue (K82, Pyrococcus furiosus 
TrpB, PfTrpB, numbering) through a protonated Schiff-base 
linkage referred to as the internal aldimine, E(Ain) (λmax= 412 
nm).[20] In the first stage of the catalytic cycle (Scheme 2), Ser 
enters the active site and replaces the lysine via transimination to 
form an external aldimine intermediate, E(Aex1) (λmax= 428 nm). 
This step is concomitant with a rigid-body conformational change 
in the TrpB COMM domain, with the enzyme adopting a ‘partially 
closed’ state.  
PLP-dependent enzyme specificity is largely dependent on 
alignment of the bond to be broken with the π molecular orbital 
system of PLP.[21–23] TrpB promotes Cα deprotonation by using a 
hydrogen bonding network formed with the Ser carboxylate that 
locks the C–H bond periplanar to the PLP π system.[23] The free 
K82 residue deprotonates the Cα of Ser, ablating the chiral center 
and forming a carbanion that is delocalized by the PLP cofactor 
to form a quinonoid intermediate, E(Q1) (λmax= 470 nm).[24] 
Subsequent elimination of the hydroxyl group forms the 
electrophilic amino-acrylate species, E(A-A) (λmax= 350 nm), 
which is poised for attack by the indole nucleophile. During this 
step, the COMM domain assumes a ‘fully closed’ conformation 
that is stabilized by TrpA.[17,25] If no indole is present, a kinetically 
competing transimination reaction with the active site lysine can 
occur, releasing dehydroalanine that hydrolyzes to form ammonia 
and pyruvate (β-elimination pathway).[26] If indole is present, it 
arrives in the active site of TrpB and is positioned by the catalytic 
glutamate (E104, PfTrpB numbering) for nucleophilic attack. The 
catalytic glutamate is important for controlling the regioselectivitiy 
of the reaction; mutagenesis reveals its crucial role to effect C–C 
bond formation at C3 over a C–N bond at N1.[27]  
The beginning of the second stage of the TrpB catalytic 
cycle is marked by irreversible nucleophilic attack by indole on the 
E(A-A) to form a second quinonoid intermediate, E(Q2) (λmax= 
~476 nm). The (S)-indolenene species is quickly deprotonated, 
restoring aromaticity, to reach a third and final quinonoid 
intermediate, E(Q3) (λmax= 476 nm).[28] Cα is then re-protonated 
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by K82 stereospecifically to form the Trp-bound external aldimine, 
E(Aex2) (λmax= 420 nm), re-establishing the chiral center and 
completing Trp formation.[29,30] Trp release from the enzyme via 
transimination by K82 returns PLP to the E(Ain) resting state and 
completes the catalytic cycle.[30] 
  
Scheme 2. Catalytic cycle of TrpB.  
2. Synthesis of noncanonical Trp derivatives 
Tryptophan derivatives (Scheme 3) are a subclass of 
ncAAs that have been used extensively as probes for chemical 
biology. Trp itself is a major source of UV absorption and 
fluorescence in proteins, and its spectral properties, which are 
highly influenced by the surrounding environment, have been 
leveraged to study protein dynamics, folding, and ligand 
binding.[31] Substitutions on the indole moiety, such as in 4-
cyanoTrp and 5-hydroxyTrp, as well as Trp isosteres like azaTrps 
(1, 2, 3, 4) can enhance or alter these spectroscopic properties to 
exhibit higher quantum yields or shift excitation/emission 
spectra.[32–34] Decorations and substitutions on the indole side 
chain bestow many other useful biochemical properties: 
fluorinated Trps are used in 19F NMR studies,[35] selenophene and 
thienyl functional groups are used for phasing crystallographic 
structures,[36] and halides can allow for site-specific modification 
through palladium-catalyzed coupling reactions with alkenes and 
alkynes.[37] Like many other ncAAs, Trp derivatives are 
biosynthetic precursors to compounds that exhibit diverse 
pharmacological activities, including anticancer, antibiotic, 
immunosuppressant, and phytotoxic properties.[38,39] 
Shortly after the discovery of TrpS, researchers began using 
substituted methylindoles (2-, 4-, 5-, 6-, 7-CH3-indole) to gain 
insights into the enzyme’s mechanism and pathway 
regulation.[29,40,41] The synthetic utility of TrpS, however, was first 
realized in 1974 when Wilcox synthesized a series of Trp 
derivatives (5-F-, 6-F-, 5-OH-, 5-MeO-, 6-MeO-, 2-CH3-, 5-CH3-, 
7-CH3-Trp; 1, 4) from Ser and indole analogs using TrpS from 
Escherichia coli (EcTrpS).[42] During the following decades, 
various wildtype TrpS homologs were shown to have activity on a 
number of other decorated indoles and indole isosteres: Saito et 
al. demonstrated the synthesis of azido-substituted Trps (4-, 5-, 
6-, 7-N3-Trp) using a TrpS from Neurospora crassa;[43] the Phillips 
group applied TrpS from Salmonella typhimurium for the 
synthesis of chloroTrps (4-, 5-, 6-, 7-Cl-Trp),[44] sulfur, selenium, 
and oxygen-containing Trp isosteres (5, 6, 7, 8, 9),[45–47] as well 
as azaTrps (1, 2, 3, 4);[48] Goss and colleagues prepared an 
exceptionally diverse set of substituted Trp analogs including 
methyl- (2-, 4-, 5-, 6-, 7-CH3-Trp),[49] amino- (4-, 6-, 7-NH2-Trp),[50] 
halo- (4-, 5-, 6-, 7-F; 4-, 5-, 6-, 7-Cl; 5-, 6-, 7-Br; 7-I-Trp),[49–52] and 
nitroTrp (7-NO2-Trp)[52] using TrpS from E. coli and Salmonella 
enterica. TrpS has also been found to catalyze a C–N bond 
forming reaction with indoline to form dihydroisotryptophan 
(10).[27,53,54] 
Despite this ability to produce desirable compounds, TrpS 
still has limitations that restrict practical and widespread use. 
Even under optimized conditions, ncAA yields with TrpS catalysts 
are typically under 50%.[49,52] Insolubility of indole compounds in 
water also limits the substrate concentrations. Although this was 
partially remedied by addition of co-solvents, the TrpS homologs 
used lacked solvent tolerance, limiting the effectiveness of this 
solution.[44] Furthermore, extensive engineering of the TrpB 
subunit for improved activity or expanded substrate scope was 
impeded by the need for the TrpA subunit, which does not directly 
participate in the coupling of indole and Ser but nonetheless 
increases metabolic load on host cells. Unfortunately, without co-
expression and allosteric activation from their corresponding 
TrpAs, native TrpBs lose most of their activity, rendering them all 
but useless.[30,55,56] 
2.1 Engineering a stand-alone TrpS β-subunit (TrpB) 
In 2015, Andrew Buller’s team engineered the wild-type 
TrpB subunit from the hyperthermophilic archaeon Pyrococcus 
furiosus (PfTrpBWT) using directed evolution to recapitulate 
allosteric activation without TrpA.[56] Using a TrpB derived from a 
hyperthermophilic organism enabled implementation of a heat-
lysis pre-treatment, which selects against enzyme variants that 
have acquired destabilizing mutations, therefore maintaining 
enzyme stability over multiple rounds of evolution. Thermostability 
also simplifies enzyme purification from the mesophilic E. coli host 
and allows screening at elevated temperatures (55–75 °C) that 
increase indole solubility and thus enable higher substrate loading. 
Only three rounds of directed evolution and six mutations were 
needed to increase the catalytic efficiency of PfTrpBWT 83-fold, 
resulting in a stand-alone variant, PfTrpB0B2, that was even more 
active than the native TrpS complex. These mutations were found 
to accelerate catalysis through the same mechanism as TrpA 
effector binding, by altering the energetics of the numerous 
transition states of TrpB.[57] When tested against a panel of 
diverse indole derivatives (2-CH3-, 4-F-, 5-F-, 5-Br-, 6-OH-, 2-aza-, 
7-aza-indole; indazole), PfTrpB0B2 retained the substrate range of 
PfTrpS, and in almost all cases initial reaction rates were 
comparable to or better than the wild-type complex. This 
N
O
P
N H
P
Lys82
NH2
N
O
P
N H
O
O
P
N
H
N
O
P
N
O
O
N
O
N H
H
O
O
HO
HO
E(Ain)
λ = 412 nm
“Open”
E(A-A)
λ = 350 nm
“Closed”
α-keto acid
λ = 320 nm
NH3 +
H2O
O
O
O
O
O
NH2
β-elimination
O
N
O
P
N
O
O
Lys82
NH2
N
H
N
O
P
N
O
O
Lys82
H2N
N
H
H
N
O
Glu104
Ser
indole
Trp
N
O
N
O
O
E(Aex1)
λ = 428 nm
“Partially closed”
E(Q1)
λ = 470 nm
E(Q2)
λ = ~476 nm
E(Q3)
λ = 476 nm
E(Aex2)
λ = 420 nm
H
H
Lys82
HH
H
H
O
O
NH
10.1002/cbic.202000379
Ac
ce
pt
ed
 M
an
us
cr
ip
t
ChemBioChem
This article is protected by copyright. All rights reserved.
 REVIEW          
4 
 
engineered TrpB activation laid the foundation for expansion of 
the enzyme’s substrate scope by directed evolution. 
  
Scheme 3. (a) TrpS- and TrpB-catalyzed synthesis of Trp analogs. (b) TrpB-
catalyzed synthesis of β-branched Trp analogs. (c) TrpS/TrpB substrate profile: 
modified indoles that any TrpS or TrpB variants have been demonstrated to 
accept. Position represents carbon where substitution, R, occurs on indole 
moiety. The profile is not to be interpreted as a TrpS/TrpB selectivity profile and 
gaps in activity may be due to lack of testing (not all indole derivatives are readily 
available). (d) Other tryptophan isosteres: TrpS and TrpB catalyze the synthesis 
of a number of Trp analogs bearing heteroatom substitutions. 
2.2 Engineering stand-alone TrpB for indole-derived 
nucleophiles 
Enzyme homologs are valuable assets that often display 
divergent activities with non-natural substrates. Javier Murciano-
Calles and co-workers investigated homologs of PfTrpB for 
activity on 5-substituted indoles.[58] They recombined activating 
mutations discovered by Buller et al. into the TrpB derived from 
the hyperthermophilic bacterium Thermotoga maritima (TmTrpB, 
64% sequence identity to PfTrpB) and found a variant with broadly 
improved activity toward 5-substituted indoles (5-CH3-, 5-OCH3-, 
5-Cl-, 5-Br-, 5-NO2-, 5-CHO-, 5-CN-, 5-B(OH)2-Trp) compared to 
previous catalysts. 
With a set of stand-alone TrpB enzymes that were 
straightforward to express and engineer in hand, David Romney 
and his team aimed to broaden the platform’s substrate scope to 
include challenging indoles on which TrpS had previously shown 
poor activity.[56,58] The resultant panel of evolved TrpB enzymes 
accepted indoles bearing different substitution patterns and 
functional moieties such as halogen (4-F-; 6-, 7-Cl-; 4-, 6-, 7-Br-; 
5-, 7-I-; 5,6-Cl2-, 5-Br-7-F-, 5-Cl-7-I-Trp), nitro (4-, 5-, 6-, 7-NO2-
Trp ), cyano (4-, 5-, 6-, 7-CN-Trp), carboxamide (5-CONH2-Trp), 
boronate (5-, 6-B(OH)2-Trp), and trifluoromethyl groups (5-CF3-
Trp) with most isolated yields ranging from 70-99%.[13] Christina 
Boville and colleagues continued engineering one of Romney’s 
variants, TmTrpB2F3, to improve activity for 4-cyanoTrp, a useful 
blue fluorescent ncAA with high quantum yield and lifetime.[59] 
This transformation demonstrated a marked improvement over 
the best synthetic route, which was a palladium-catalyzed 
cyanation reaction that achieved a maximal yield of 10%.[32] Cells 
from one liter of E. coli shake flask culture expressing the final 
variant, TmTrpB9D8*, could synthesize 4-cyanoTrp on a larger 
scale (800 mg, 49% yield). Notably, laboratory-evolved 
TmTrpB9D8* was discovered to function better at lower 
temperatures (such as 37 °C), providing for future possible in vivo 
applications.[59] 
2.3 β-Branched Trps  
Beta-branched amino acids are found in many useful 
bioactive natural products and pharmaceuticals; however the 
presence of two adjacent chiral centers makes them particularly 
challenging to synthesize.[60,61] Buller’s team engineered their 
stand-alone TrpB to accept L-threonine (Thr) as the electrophile 
to produce β-methylTrp (Scheme 3b).[62] Unlike in earlier works, 
where modified electrophiles ultimately produced the same 
amino-acrylate as Ser,[63,64] the use of Thr generated an entirely 
new β-substituted amino-acrylate-like species (amino-crotonate) 
that diastereoselectively formed a second chiral center upon C–C 
bond formation. This is remarkable: Thr is a universal and 
abundant metabolite that TrpS naturally discriminates against. 
Buller discovered that native TrpS actually binds Thr efficiently, 
but binding results in decreased affinity for indole and disrupts the 
allosteric signaling that regulates the catalytic cycle. These effects 
translate to a >82,000 fold-preference for Ser over Thr in the 
native enzyme complex when both substrates are present.[65] 
However, in the absence of Ser competition, PfTrpS—and more 
importantly PfTrpBWT—showed trace activity with indole and Thr, 
providing the foothold necessary to apply directed evolution. 
Starting from an evolutionary intermediate from their previous 
campaign that had better activity with Thr than the wild-type 
enzyme, PfTrpB4D11, two rounds of evolution accumulating three 
new mutations resulted in PfTrpB2B9, which exhibited a >6,000-
fold boost in activity for β-methylTrp formation relative to wild-type 
PfTrpB.[62] 
Shortly after this work appeared, the Micklefield group 
published an engineered StTrpS bearing one mutation, L166V, 
that could also catalyze the formation of β-branched Trps (β-
methyl- ; β-methyl-2-, 4-, 6-, 7-CH3-; β-methyl-4-, 7-F-; β-methyl-
7-Cl-; β-methyl-7-OMe-Trp) from Thr and indole analogs.[66] 
Similar to PfTrpS, the enzyme struggled with 5-substituted indoles. 
Instead of applying further evolution to increase the substrate 
scope, the authors took a different approach, using StTrpSL166V to 
synthesize β-methylTrp (11), which they then derivatized 
chemoenzymatically. The flavin-dependent Trp-5-halogenase 
PyrH was used with MgCl2 or NaBr to create halogenated 5-
substituted Trps (5-Br-, 5-Cl-Trp) which could undergo a 
palladium-catalyzed cross coupling reaction with phenylboronic 
acid in the same pot to create 5-phenyl-β-methylTrp (Scheme 4, 
12). 
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Scheme 4. One-pot C5-arylation of β-methylTrp (11). Flavin-dependent Trp-
halogenase PyrH brominates C5, which then participates in a palladium-
catalyzed Suzuki cross-coupling to install the aryl group (12).[66] 
Christina Boville and team engineered stand-alone 
PfTrpB2B9 to accept β-branched Ser analogs with longer alkyl 
chains such as β-ethyl- and β-propylSer.[67] Bulkier alkyl chains at 
the β-position were thought to hinder nucleophilic attack, allowing 
the competing β-elimination to unproductively consume the 
electrophile. Initial activity with PfTrpB2B9 on β-ethylSer and indole 
was too low for high-throughput screening, so the authors 
mutated an active-site residue presumed to clash sterically with 
the alkyl β-substitution. Investigating the very same residue 
mutated by Micklefield et al.,[66] Boville and colleagues discovered 
that both valine (Val) and alanine (Ala) improved activity. While 
Ala was slightly less beneficial than Val, the authors rationalized 
that Ala may provide more room in the active site for electrophiles 
with longer β-alkyl substituents. This boosted activity enough to 
enable Boville’s team to use a high-throughput UV-based screen 
with libraries generated by random mutagenesis for three more 
rounds of evolution. The final variant, PfTrpB7E6, was assayed 
against combinations of electrophiles (Thr, β-ethyl-, β-propylSer) 
and nucleophiles (indole; 2-, 4-, 5-, 6-, 7-CH3-; 4-, 5-F-; 5-Cl-; 7-
aza-indole) to determine its substrate scope and generality. 
Although PfTrpB7E6 was only evolved on β-ethylSer, the mutations 
substantially improved activity for Thr and β-propylSer as well. 
Notably, PfTrpB7E6 required only one equivalent of Thr to achieve 
a 3.5-fold greater yield for β-methylTrp than the parent PfTrpB2B9 
did with ten equivalents of Thr. X-ray crystallography, 
measurement of the deamination rates and UV-
spectrophotometric evidence supported the hypothesis that 
evolution stabilized the closed conformation of the enzyme and 
generated a more persistent amino-acrylate that was less prone 
to unproductive β-elimination .[67] 
2.4 Engineering stand-alone TrpB for non-indole-derived 
nucleophiles 
TrpB proved its mettle as a noncanonical Trp synthase, but 
it remained to be seen whether the enzyme could become a more 
generalized ncAA synthase. The observation of activity with thiol- 
and nitrogen-based nucleophiles provided precedent for the 
possibility that TrpB can accept molecules that are not explicitly 
indole-like to create C–N,[27,54,56,68,69] C–S,[70] and C–Se[70] bonds 
(Figure 1). In principle, any sufficiently activated nucleophile that 
fits in the active site could react with the amino-acrylate. Carbon-
based nucleophiles would be attractive synthons for TrpB, 
allowing for enzymatic C–C bond formation to make a broad panel 
of ncAAs. One major challenge, however, is that strong carbon-
based nucleophiles, which are normally accessed via 
deprotonation of weakly-acidic C–H bonds, are highly disfavored 
in water because of their high basicity (pKa > 7). Nevertheless, 
enzymes are known to exert profound effects on substrates to 
lower activation barriers, making the endeavor at least worth 
investigation. To our surprise and satisfaction, we discovered 
TrpB can react with a number of carbon nucleophiles to form 
novel ncAAs.  
Nitroalkanes readily tautomerize to form a nucleophilic 
carbon alpha to the nitro group and have been used in the past 
as substrates for C–C bond formation reactions with electrophile-
activating enzymes.[71–73] They have also been shown to react 
with chemically formed amino-acrylates to synthesize a wide 
range of amino acids, albeit under harsh conditions and with no 
enantioselectivity.[74–77] This led David Romney to hypothesize 
that nitroalkanes could act as nucleophiles in the TrpB β-
elimination reaction.[78] This was indeed the case, and many of the 
pre-existing TrpB variants they tested displayed at least some 
activity with (nitromethyl)benzene (Scheme 5, a) and the more 
sterically unwieldy nitrocyclohexane (Scheme 5, b). At the 
standard screening temperature of 75 °C, (nitromethyl)benzene 
was found to decompose, leading the authors to reduce the 
reaction temperature to 50 °C. The variant with the best activity 
on both substrates was subjected to several rounds of site-
saturation mutagenesis (SSM) targeting the active site to 
ultimately produce two specialized variants that both exhibited a 
maximum of 2,700 turnovers with their respective substrates. 
Because nucleophilicity is dependent on pH, the authors 
investigated the effect of pH and discovered that higher pH (pH 
9.0) did not necessarily improve the initial reaction rate but did 
result in higher total turnovers and consequently higher yield. The 
authors probed the substrate scopes of the two enzymes with a 
panel of nitrocyclohexane and (nitromethyl)benzene derivatives 
(Scheme 5, boxed). Unfortunately, the carbon alpha to the nitro 
group is still readily deprotonated after product formation, 
resulting in stereoablation of the products with newly formed chiral 
centers. Nevertheless, the authors suggested that the platform 
could be engineered for α-nitro-substituted substrates to 
synthesize ncAAs with multiple chiral centers. 
Biologically active compounds are replete with all-carbon 
quaternary centers whose regio- and stereoselective formation is 
a challenge for both organic synthesis and biocatalysis. In a 
recent study, Markus Dick and Nicholas Sarai engineered TrpB 
for selective quaternary bond formation with 3-substituted 
oxindoles.[79] 3,3-Disubstituted oxindoles are a common motif in 
natural and synthetic bioactive compounds. Similar to the 
tautomerization of nitroalkanes to form a nucleophilic carbon, 
oxindoles exist in an equilibrium between keto and enol tautomers, 
the latter of which is nucleophilic. In contrast to the nitroalkanes, 
whose tautomerization in water could be readily observed by 
NMR, the equivalent tautomer could not be observed for 
oxindoles, which suggested that there could be a significant 
activation barrier for TrpB to overcome in order for nucleophilic 
attack to occur. 3-Methyloxindole (17) was initially tested due to 
its abundance in synthetic and natural compounds. However, the 
methyl group appeared to sterically hinder nucleophilic attack 
from C3, and the initial TrpB variants that were tested primarily 
formed the N-alkylation product (Scheme 6, 18). A few variants, 
however, also formed the desired C3-alkylation product, providing 
a foothold for directed evolution. To prevent N-alkylation, Dick and 
Sarai chose to use 1,3-dimethyloxindole (1-CH3-17) as the model 
substrate to begin evolution. Impressively, a single generation 
was enough to switch the chemoselectivity almost entirely from 
N- to C3-alkylation, allowing the authors to continue with their 
original substrate, 3-methyloxindole, for the remainder of the 
evolution. After three more rounds of mutagenesis and screening, 
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they obtained variant PfTrpBquat that exhibited >99% 
chemoselectivity for C3-alkylation and a 52% yield (122 mg) from 
1 mmol of 3-methyloxindole using only 100 mL of E. coli cell 
culture. They determined that the enzyme was S,S-
stereoselective with 3-methyloxindole, though stereoselectivity 
decreased with bulkier substitutions at C3. The enzyme could also 
tolerate ketone and lactone structures, demonstrating its ability to 
create quaternary centers with a diverse suite of carbonyl-
containing nucleophiles bearing a tertiary carbon (Scheme 6, 
solid black box and dashed pink box). 
The ability of TrpB to accept non-indole substrates such as 
nitroalkanes and oxindoles inspired other members of our lab to 
explore more molecules with known nucleophilic character such 
as the cyclic aromatic hydrocarbon azulene (Scheme 7, 29). Until 
this point carbon nucleophiles accepted by TrpS and TrpB 
possessed heteroatoms that could stabilize the accumulation of 
charge during nucleophilic attack. Although azulene has no 
heteroatoms, it experiences a permanent dipole readily apparent 
in its resonance structure, which is a cycloheptatrienyl cation 
(tropylium) fused to a cyclopentadienyl anion (Cp–). We 
hypothesized that the electron accumulation of the Cp– stabilized 
by the tropylium system could promote nucleophilic attack by 
azulene on the amino-acrylate to form the ncAA β-(1-azulenyl)-L-
alanine (Scheme 7, AzAla, 30).[80] AzAla is a blue Trp isostere 
whose fluorescent properties have been leveraged for 
spectroscopic studies,[81–83] but whose use was limited due to its 
difficult, time-sensitive, multi-step synthesis.[84] 
  
Figure 1. Products of non-carbon and non-indole nucleophiles produced by TrpS and TrpB. [27,54,56,68–70] 
  
Scheme 5. Reaction scheme and product scope (boxed) of engineered TrpB with nitroalkanes as nucleophiles for ncAA synthesis. Nitroalkanes readily tautomerize 
in water to form a nucleophilic carbon species that reacts with the amino-acrylate intermediate in TrpB to form a new C–C bond. Model substrates a and b (dashed 
box) were used for directed evolution of TrpB.[78]  
  
Scheme 6. Reaction scheme and product scope (boxed) of oxindoles as nucleophiles for TrpB-catalyzed ncAA synthesis. Initially, TrpB variants catalyzed primarily 
N-alkylation of 17 to form 18. With directed evolution, the regio- and chemoselectivity were switched to favor the desired C–C product (19, green dashed box). The 
final evolved variant accepted oxindoles with aryl (20, 21), N-methyl (22), and C3 substitutions (23, 24, 25, black box). It also catalyzed the formation of lactone (26) 
and cyclic ketone (27 & 28) products (pink dashed box), which suggests that evolution could be applied to expand the scope of ncAA synthesis to encompass other 
nucleophiles.[79]  
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Scheme 7. TrpB-catalyzed synthesis of β-(1-azulenyl)-L-alanine (AzAla) (30) 
from azulene (29) and serine.[80] 
Azulene was tested against a diverse panel of engineered 
TrpB variants, and nearly every enzyme demonstrated significant 
activity for the reaction, the exception being variants bearing a 
glycine mutation at the highly conserved catalytic glutamate 
(E104G, PfTrpB numbering). We reasoned that the catalytic 
glutamate may be important for stabilizing the tropylium cation to 
facilitate the nucleophilic attack from Cp- (Figure 2). This 
hypothesis was supported by examining azulene and indole 
activity with PfTrpB and TmTrpB variants with and without the 
glutamate to glycine mutation. While the mutation only attenuated 
Trp formation and decreased regioselectivity, it completely 
abolished AzAla formation, demonstrating a critical role for this 
residue in the non-natural reaction. 
  
Figure 2. Comparison of proposed mechanism of nucleophilic activation in the 
TrpB active site for native substrate indole (a) and azulene (29) (b). Figure 
adapted from ref. [80]. Copyright: 2020, ChemBioChem. 
Azulene was found to sublime readily at higher 
temperatures, making its containment at 75 °C difficult. Although 
many TrpB variants were good candidates for evolution, 
TmTrpB9D8* was chosen due to its good activity at the lower 
temperatures used to mitigate substrate loss. It took only one 
round of evolution and two mutations (W286R and F184S) to 
improve the turnover rate of TmTrpB9D8* three-fold (from 4.6 to 
14.0 turnovers per minute). The final variant, TmTrpBAzul, was 
used to synthesize AzAla on gram scale (965 mg, 57% isolated 
yield).[80] 
3. Biocatalytic cascades 
Designing and optimizing enzymatic cascades can be a 
laborious process, and to date many do not best their synthetic 
rivals. Nonetheless, their continued development is paramount for 
realizing the potential of biocatalysis as a sustainable route to 
many of the world’s chemicals. The ever-expanding catalog of 
engineered biocatalysts and advances in metabolic engineering 
have transformed the once pipe dream of whole-cell biocatalytic 
cascades into an attainable reality. In this realm, stereo- and 
regioselective enzymes that can be engineered easily and 
expressed heterologously reign supreme. It is thus not surprising 
that TrpS and TrpB—which are simple to use and boast large 
scopes of biologically relevant products—have already been used 
in a number of cascades. Some of the in vivo implementations 
have required only the host’s native TrpS, which speaks to the 
latent potential of this remarkable complex. Others have made 
use of the simplicity provided by the stand-alone TrpB platform. In 
the following section, we highlight notable applications of TrpS 
and TrpB in biocatalytic cascades and discuss their 
biotechnological relevance. 
3.1 D-Amino acids 
Although L-amino acids comprise an overwhelming majority 
of amino acids in natural and synthetic compounds, their mirror 
counterparts are still found in many bioactive molecules and are 
important targets for enantiopure synthesis. D-amino acids face 
similar synthetic challenges to L-amino acids but lack their diverse 
abundance of synthases, making direct biocatalytic access 
difficult. Unfortunately, TrpS’s strict retention of stereoselectivity 
for making the L-amino acid hinders its ability to be repurposed as 
a D-amino acid synthase. Nevertheless, because TrpS still 
represents a simple way to make Trp derivatives, numerous 
groups have combined TrpS with downstream enzymes to access 
various D-Trps. 
Parmeggiani and colleagues coupled TrpS from S. enterica 
(SeTrpS) with an L-amino acid deaminase (LAAD) followed by an 
engineered D-alanine aminotransferase (DAAT) to synthesize D-
Trp derivatives in a one-pot, two-step transformation (Scheme 
8).[85] LAAD and DAAT were found to possess promiscuous 
activity for L-Ser, putting Ser in direct competition with L-Trp for 
stereoinversion and lowering the overall enantiomeric excess (ee) 
of the product. To circumvent this, the cascade was converted into 
a one-pot telescopic system whereby the stereoinversion 
biocatalysts were introduced after the TrpS-mediated synthesis 
was complete. This proved to be an effective strategy to 
synthesize numerous D-Trp derivatives at gram scale with high 
yields and high ee. 
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Scheme 8. Biocatalytic cascade for synthesis of D-Trp derivatives. In the first 
reaction, a substituted indole is transformed into its respective Trp derivative by 
TrpS. In the second reaction, an L-amino acid deaminase (LAAD) deaminates 
the Trp to form an imine intermediate, which then spontaneously hydrolyzes to 
the α-keto acid. A D-alanine aminotransferase (DAAT) transaminates the α-keto 
acid with D-Asp, forming oxaloacetate and the D-Trp. Adapted with permission 
from ref. [85]. Copyright: 2019, ACS Catalysis. 
In their preparation of β-branched Trps using TrpS, the 
Micklefield group used an L-amino acid oxidase (LAAO) and 
excess ammonia borane to produce the enantiopure D-configured 
epimer of β-methylTrp (Scheme 9, (2R,3S)-β-methylTrp, 32).[66] 
Ammonia borane nonspecifically reduces the imine product 
formed by the LAAO to form both the L- and D-amino acids; LAAO 
re-oxidizes the L-isomer to the imine while the D-isomer 
accumulates. The synthesis was performed in two steps in 
separate pots and resulted in an overall yield of 66%. While the 
authors only demonstrated this proof of concept with β-methylTrp 
(31), the LAAO they used exhibits a broad substrate scope, and 
it is likely the method could be used to make other derivatized D-
β-branched Trps.[86] 
 
Scheme 9. One-pot chemoenzymatic approach for the stereoinversion of β-
methylTrp (31) to form D-β-methylTrp (32).[66] 
3.2 Tryptamine products 
In addition to its essential role as a proteinogenic amino acid, 
Trp is a precursor to numerous primary and secondary 
metabolites across all domains of life.[87] Tryptamines are one 
such class of Trp-derived molecules that possess a wide range of 
bioactive properties. Reflecting their importance, significant 
efforts to develop synthetic approaches for tryptamines have 
resulted in several effective methodologies.[88–91] However, there 
is still room for biocatalysis to improve upon the cost, 
sustainability, and level of oversight needed for their synthesis. 
Recently, there has been interest in the study of psychoactive 
natural products like psilocybin as treatments for psychological 
and neurological afflictions. Psilocybin is a hallucinogenic 
tryptamine that is an effective treatment option for patients with 
anxiety,[92] substance addiction,[93,94] and depression,[95,96] and it is 
possible that the molecule will be approved as a pharmaceutical 
drug. Unfortunately, psilocybin is produced only in very small and 
inconsistent amounts by the mushroom Psilocybe cubensis, 
making commercial extraction impractical.[97] 
Recent elucidation of the natural biosynthetic pathway by 
the Hoffmeister group revealed that TrpS lies upstream of only 
four enzymes, PsiH, PsiD, PsiK, and PsiM (which provide 
monooxygenase, decarboxylase, kinase, and methytransferase 
activities, respectively) to reach psilocybin (Scheme 10, black 
arrows).[98] The relative simplicity of the pathway coupled with the 
product’s newfound pharmacological relevance encouraged them 
to investigate whether the cascade could be expressed in a model 
host organism to provide a scalable biosynthetic route. Indeed, 
the proteins expressed in E. coli allowed Fricke et al. to validate 
the putative activities of each enzyme and demonstrate an in vitro 
biosynthetic cascade of psilocybin.[99] In characterizing the 
enzymes, they discovered, perhaps unsurprisingly, that P. 
cubensis TrpB (PcTrpB) could accept 4-hydroxyindole to produce 
4-hydroxyTrp. Fortuitously, PsiD could accept 4-hydroxyTrp, 
which obviated the need for PsiH and further simplified the in vitro 
synthesis to a four-enzyme cascade that starts from 4-
hydroxyindole (Scheme 10, dashed arrows).  
Since then, there have been several instantiations of the 
cascade in different hosts. The first in vivo attempt ported the four 
enzymes downstream of TrpS into Aspergillus nidulans, 
accomplishing a modest 110 mg/L titer and more importantly 
establishing precedence for further in vivo applications.[100] 
Adams et al. transferred the cascade without PsiH into E. coli, 
instead exploiting the promiscuity of EcTrpS to synthesize 4-
hyroxyTrp from 4-hydroxyindole that was provided 
exogenously.[101] Attempts at EcTrpS overexpression did not 
improve titer, with native levels of expression sufficient for the 
pathway’s flux. Scale up led to 1.16 g/L of psilocybin after 72 
hours, a ten-fold enhancement over the previous method. Most 
recently, Milne et al. transferred the entire pathway into 
Saccharomyces cerevisiae for the de novo biosynthetic 
production of psilocybin.[102] They chose to use the natural 
functionality of TrpS to engineer a biosynthetic route to psilocybin 
rather than exploit the enzyme’s promiscuity for relatively costly 
4-hydroxyindole. A fed-batch fermentation process yielded 627 
mg/L of psilocybin and 580 mg/L of psilocin, the dephosphorylated 
bioactive form of psilocybin, after 200 hours. However, their 
metabolically engineered pathway takes about three-fold longer 
to reach approximately the same titer as the in vivo pathway 
starting from 4-hydroxyindole put forth by Adams et al.[101]
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Scheme 10. Enzymatic synthesis of psilocybin. Black arrows represent natural pathway and pathway implemented by Milne et al. in S. cerevisiae.[102] Dashed 
arrows represent synthetic pathway that exploit promiscuity of TrpS to synthesize 4-hydroxyTrp from 4-hydroxindole.[99,101] 
   
Scheme 11. One-pot, two-step synthesis of tryptamine derivatives with TrpB and and Ruminococcus gnavus Trp decarboxylase (RgnTDC). Top: reaction scheme, 
bottom boxed: product scope.
Psilocybin is one of the most well-known examples of a 
tryptamine, perhaps second only to the neurotransmitter 
serotonin. However, tryptamines are an abundant motif among 
alkaloid natural products, and substitutions around the aromatic 
indole ring have profound effects on their bioactive properties. In 
Nature, substitutions are installed after Trp biosynthesis by 
specific enzymes, not unlike the natural psilocybin pathway. 
Harnessing these enzymes for biocatalysis to produce tryptamine 
derivatives, however, presents the arduous task of identifying and 
expressing separate tailoring enzymes for different Trp 
modifications.[103] 
The modular and convergent nature of TrpB to combine 
substituted indoles with Ser offers a simpler and more general 
method to access Trp analogs. Buller and colleagues 
hypothesized that coupling a stand-alone TrpB with a 
promiscuous Trp decarboxylase would create a simple and 
streamlined route to diverse tryptamines.[104] No Trp 
decarboxylases that accept a broad range of substrates had been 
reported, so they tested a variant from the gut microbe 
Ruminococcus gnavus (RgnTDC), whose active site appeared to 
be large enough to accommodate substituted indoles. RgnTDC 
possessed relatively high promiscuous activity suitable for 
immediate biocatalytic application with TrpB. Because the two 
enzymes operate at dramatically different optimal temperatures 
(75 vs. 37 °C), PfTrpB2B9 was combined with RgnTDC in a one-
pot, two-step reaction to produce a range of tryptamine 
derivatives with isolated yields ranging from 12-99% (Scheme 11). 
The ability to access a large number of products by combining 
TrpB and RgnTDC is a testament to the versatility and power that 
generalist enzymes bring to biocatalysis. 
5. Summary and outlook 
TrpS is a remarkable enzyme and ideal ncAA synthase. Its 
long history as a model enzyme led to substantial knowledge 
about its allosteric regulation and catalytic mechanism that 
granted enzyme engineers the ability to re-imagine its function. In 
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this review, we have covered major applications of TrpS, from 
humble beginnings preparing simple Trp analogs to becoming a 
powerful platform of TrpB enzymes that produce entirely new-to-
nature ncAAs, as well as its use in biocatalytic cascades to make 
new Trp-derived products. The no-frills TrpB platform dramatically 
simplifies enzyme engineering efforts, enabling the rapid 
expansion and exploration of the synthase’s substrate scope. 
Recent success in evolving TrpB to catalyze C–C bonds with new, 
non-indole nucleophiles bodes well for the platform’s further 
expansion into ncAA space. We envision that the discovery of 
highly stable and evolvable TrpB variants that function well at 
moderate temperatures will promote future applications in 
cascades, replacing multi-step syntheses that currently must 
accommodate different temperature optima. Mesophilic TrpB 
variants may also be used for in vivo synthesis to improve 
intracellular delivery of the ncAA (indole passes through cellular 
membranes more readily than a charged amino acid), reducing 
the amount of product that must be supplied exogenously, which 
could improve incorporation rates and reduce costs. In vivo 
synthesis and incorporation of ncAAs into proteins or secondary 
metabolites might also be used for robust 
biocontainment.[101,105,106] 
Although many substituted indoles are commercially 
available, one of the roadblocks for biocatalytic synthesis of Trp 
derivatives by TrpS and TrpB is the high price and limited 
availability of these substrates. This issue is highlighted by Milne 
et al., who used PsiH to install a hydroxyl group on Trp rather than 
provide expensive 4-hydroxyindole to TrpS directly.[102] However, 
as we reach beyond the domain of naturally occurring chemical 
motifs, it is more difficult to find enzymes like PsiH that can make 
desired Trp modifications. In this non-natural space the TrpB 
platform truly shines for ncAA synthesis; it is simpler to engineer 
TrpB to accept new derivatives than it is to discover and engineer 
whole new enzymes that modify Trp. Therefore, advances in 
indole analog synthesis will continue to make TrpB a desirable 
route to Trp analogs. We expect that further applications of TrpS 
and TrpB are on the horizon and demonstrations like those from 
Parmeggiani et al.[85] and McDonald et al.[104] will inspire others to 
use this biocatalyst extraordinaire.  
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Biocatalyst extraordinaire! Tryptophan synthase (TrpS) natively catalyzes the formation of tryptophan but also possesses 
remarkable promiscuous activity for synthesizing a wide range of noncanonical amino acids (ncAAs). This review details the history 
of TrpS as a ncAA synthase, from the characterization of its naturally broad substrate scope and engineering efforts to expand the 
range of its non-natural chemistry to applications in biocatalytic cascades to synthesize diverse natural and xenobiotic compounds. 
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